Latest News for: vav1

Edit

InnoCare Announces IND Approval to Initiate Clinical Trial of VAV1 Degrader ICP-538 in China

Nasdaq Globe Newswire 09 Feb 2026
ICP-538 is the first VAV1 degrader approved to enter clinical trials in China and the second globally ... .
Edit

Keystone Symposia – MRT-6160, a highly selective and first-in-class VAV1-directed molecular glue degrader, demonstrates activity in multiple immune-mediated disease models (Monte Rosa Therapeutics Inc)

Public Technologies 22 Jan 2026
) MRT-6160, a highly selective and first-in-class VAV1-directed molecular glue degrader, demonstrates activity in multiple immune-mediated disease models ... Monte Rosa Therapeutics has a global exclusive license agreement with Novartis to advance VAV1.
  • 1

Article Search

tools
×
×
×
×